Vetter to build $320M plant in U.S.

When word got out last week that German CDMO Vetter would build a sterile injectables manufacturing facility in the Chicago area, details were thin. But now the company has filled them in, saying it will invest $320 million and hopes to eventually have 400 to 500 workers at the site.

Vetter is seeking approval from local authorities for permission to build out a 1.1-million-square-foot facility over a decade on an 18-acre site in Des Plaines, IL. The site used to be home to the Salvation Army’s central territory headquarters.

The facility would handle fill and finish of aseptically prefilled syringe systems, cartridges and vials and is expected to initially provide about 300 jobs, but Vetter is hoping to expand it over time. The Ravensburg, Germany-based company already has a small clinical supply facility in the nearby Village of Skokie where about 70 people work, but Vetter said it wanted to be able to offer its clients commercial manufacturing capabilities in the U.S.

Survey

Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

“Several of our customers have requested commercial manufacturing resources both in U.S. and Europe for their multifaceted market production needs,” Vetter Managing Director Peter Soelkner said in a statement.

Vetter has been expanding for several years and in 2013 announced plans to invest about $100 million in its facilities in Ravensburg and in Skokie.  

- here’s the release 

Related Articles: 
New Chicago-area plant for Germany's Vetter promises 300 jobs 
Vetter putting $100M into its production network

Suggested Articles

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.

Pfizer is ponying up $500 million on top of $100 million already committed to a gene therapy manufacturing facility in North Carolina.